Pharmaceuticals

Consolidated total income of the company stood at ₹237.74 crore for the quarter under consideration

The growth was propelled by industries like pharma, which saw 44% rise in hiring activities, FMCG (43%), education and teaching (41%) and IT (32%)

The proposed merger indicates early signs of consolidation in the e-pharmacy segment, which along with edtech platforms outperformed most startups during the lockdown period.

Sales for Rs11,250 crore was recorded, with all segments, especially chronic drugs, showing a reboundGrowth in sales for some industry-leading companies was sluggish at 0.2-1.8%, against the industry average of 2.4%

A rise in inspection of Indian pharmaceutical companies is expected as they produce new quality of drugs strongly based on their research and development programmes

Pharma companies have been lately keeping bigger inventories to avoid another lockdown-like disruption

Among the 23 industries tracked by the Central Statistics Office's Index of Industrial Production, the pharmaceuticals industry had the ninth highest growth rate.

The worst hit among the top 20 companies was Cipla, whose sales fall by 28%, while that of Zydus Cadila, GSK Pharma and Dr Reddy’s down by 25%, eachThere seemes to be less panic buying of medicines for chronic illnesses in the last two weeks of April

A primary reason for the sales growth was an increase in pricesSales of respiratory and anti-infective drugs top sales growth among various therapeutic areas during the month

A higher market share coupled with cost-control measures should help Indian firms recoup some of the lost groundThe rise in market share coincides with the change in the competitive landscape in the US drug market